Shuling Jiang - 20 May 2022 Form 3 Insider Report for ABVC BIOPHARMA, INC. (ABVC)

Reporting relationship: Director, 10%+ Owner
Issuer ticker: ABVC
Reported as of: 20 May 2022
Net transaction value: $0
SEC form: 3
Accepted by SEC: 12 Jul 2022, 17:01:09 UTC
Source filing: View source filing
Reporting owner signature: /s/ Shuliang Jiang

Key filing fact

Shuling Jiang filed Form 3 for ABVC BIOPHARMA, INC. (ABVC) on 12 Jul 2022.

Key facts

This page summarizes Shuling Jiang's Form 3 filing for ABVC BIOPHARMA, INC. (ABVC).
0 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 12 Jul 2022, 17:01.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ABVC holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 7,908,805
Date: 20 May 2022
Ownership: See Footnote
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Ms. Jiang owns 213,120 shares through Keypoint Technology Ltd., over which she has sole voting control, 538,429 through her 80% ownership of Lion Arts, 6,620,981 through Lion Arts' ownership of YuanGene Corporation, 71,685 shares through her ownership of BioFirst, 1,415 shares through her ownership of BioLite, 381,193 shares through her ownership of Liongene, 12,228 shares through her ownership of Rgene, 5,540 shares through her ownership of Genpro Investment, and 64,215 shares directly.